Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 3/2015

01-03-2015 | Review

Practical Opportunities to Improve Early Detection and Prevention of Colorectal Cancer (CRC) in Members of High-Risk Families

Authors: S. G. Patel, J. T. Lowery, D. Gatof, D. J. Ahnen

Published in: Digestive Diseases and Sciences | Issue 3/2015

Login to get access

Abstract

Colorectal cancer (CRC) incidence and mortality are steadily declining and CRC screening rates are increasing in the United States. Although this a very good news, several definable groups still have very low screening rates including younger (under age 50) members of high-risk CRC families. This opinion piece describes five strategies that could be incorporated into routine practice to improve identification and guideline-based screening in members of high-risk families. Routine incorporation of a simple family history screening tool and outreach to high-risk family members could substantially improve guideline-based screening in this population. Identification of CRCs and advanced adenomas in the endoscopy suite defines another group of high-risk families for similar outreach. Lynch syndrome families can be identified by testing CRCs and selected adenomas for microsatellite instability or loss of DNA repair protein expression. Finally, selective addition of aspirin to surveillance endoscopy can decrease the risk of new adenomas and CRCs. The rationale for these strategies as well as mechanisms for their implementation and evaluation in clinical practice is described.
Literature
1.
Patel S, Ahnen D. Screening for colon polyps and cancer. In: Miller AB, ed. Epidemiologic studies in cancer prevention and screening. Vol 79. New York: Springer, 2013:233–261.
2.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–117.CrossRefPubMed
3.
Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.CrossRefPubMedCentralPubMed
4.
Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595.CrossRefPubMed
5.
Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739–750.CrossRefPubMed
6.
7.
Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63:546–557.CrossRefPubMed
8.
Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014;109:1159–1179.CrossRefPubMed
9.
Ait Ouakrim D, Lockett T, Boussioutas A, et al. Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis. Fam Cancer. 2013;12:459–472.CrossRefPubMed
10.
Rees G, Martin PR, Macrae FA. Screening participation in individuals with a family history of colorectal cancer: a review. Eur J Cancer Care (Engl). 2008;17:221–232.CrossRef
11.
Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila). 2011;4:1–5.CrossRef
12.
Claes E, Denayer L, Evers-Kiebooms G, et al. Predictive testing for hereditary nonpolyposis colorectal cancer: subjective perception regarding colorectal and endometrial cancer, distress, and health-related behavior at one year post-test. Genet Test. 2005;9:54–65.CrossRefPubMed
13.
Collins V, Meiser B, Gaff C, et al. Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer. 2005;104:273–281.CrossRefPubMed
14.
Hadley DW, Jenkins JF, Dimond E, et al. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2004;22:39–44.CrossRefPubMed
15.
Halbert CH, Lynch H, Lynch J, et al. Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med. 2004;164:1881–1887.CrossRefPubMed
16.
Johnson KA, Trimbath JD, Petersen GM, et al. Impact of genetic counseling and testing on colorectal cancer screening behavior. Genet Test. 2002;6:303–306.CrossRefPubMed
17.
Wagner A, van Kessel I, Kriege MG, et al. Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer. 2005;4:295–300.CrossRefPubMed
18.
Lowery JT, Marcus A, Kinney A, et al. The Family Health Promotion Project (FHPP): design and baseline data from a randomized trial to increase colonoscopy screening in high risk families. Contemp Clin Trials. 2012;33:426–435.CrossRefPubMedCentralPubMed
19.
Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89:1406–1422.CrossRefPubMed
20.
Lowery JT, Horick N, Kinney AY, et al. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomarkers Prev. 2014;23:601–610.CrossRefPubMed
21.
22.
Kumaravel V, Heald B, Lopez R, et al. Patients do not recall important details about polyps, required for colorectal cancer prevention. Clin Gastroenterol Hepatol. 2013;11:e1–e2.CrossRefPubMed
23.
Brock AS, Wallace K, Romagnuolo J, et al. Patients’ short-term knowledge of personal polyp history inadequate despite systematic notification of results after polypectomy. South Med J. 2013;106:285–289.CrossRefPubMed
24.
Grover S, Stoffel EM, Bussone L, et al. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol. 2004;2:813–819.CrossRefPubMed
25.
Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol. 2002;20:528–537.CrossRefPubMed
26.
Tyler CV Jr, Snyder CW. Cancer risk assessment: examining the family physician’s role. J Am Board Fam Med. 2006;19:468–477.CrossRefPubMed
27.
Use of electronic medical records to facilitate colorectal cancer screening in community health centers. Volume 2014: National Colorectal Cancer Roundtable; American Cancer Society; National Association of Community Health Center.
28.
Kastrinos F, Allen JI, Stockwell DH, et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol. 2009;104:1508–1518.CrossRefPubMedCentralPubMed
29.
Kastrinos F, Steyerberg EW, Balmana J, et al. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut. 2013;62:272–279.CrossRefPubMedCentralPubMed
30.
Khan O, Blanco A, Conrad P et al. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011;106:1822–1827; quiz 1828.
31.
Nathanson JW, Zisman TL, Julian C, et al. Identification of patients at increased risk for colorectal cancer in an open access endoscopy center. J Clin Gastroenterol. 2008;42:1025–1031.CrossRefPubMed
32.
Klabunde CN, Vernon SW, Nadel MR, et al. Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. Med Care. 2005;43:939–944.CrossRefPubMed
33.
Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130:1865–1871.CrossRefPubMed
34.
Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–857.CrossRefPubMed
35.
Rex D, Schoenfeld P, Cohen J et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2015;81:31–53.
36.
Austin GL, Goldstein JI, Peters SL, et al. Are colorectal cancer screening recommendations for first-degree relatives of patients with adenomas too aggressive? Clin Gastroenterol Hepatol. 2011;9:308–313.CrossRefPubMed
37.
Hewitt M, Greenfield S, Ellen Stovall (eds). Committee on Cancer Survivorship: Improving Care and Quality of Life, National Cancer Policy Board. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press, 2005.
38.
de Vos tot Nederveen Cappel WH, Jarvinen HJ, Lynch PM, et al. Colorectal surveillance in Lynch syndrome families. Fam Cancer. 2013;12:261–265.CrossRefPubMed
39.
Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155:69–79.CrossRefPubMedCentralPubMed
40.
41.
Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89:1758–1762.CrossRefPubMed
42.
Teutsch SM, Bradley LA, Palomaki GE, et al. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med. 2009;11:3–14.CrossRefPubMedCentralPubMed
43.
Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–957.CrossRefPubMed
44.
Natarajan N, Watson P, Silva-Lopez E, et al. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum. 2010;53:77–82.CrossRefPubMed
45.
Fadhil W, Ibrahem S, Seth R, et al. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. Histopathology. 2012;61:1117–1124.CrossRefPubMed
46.
Walsh MD, Buchanan DD, Pearson SA, et al. Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry. Mod Pathol. 2012;25:722–730.CrossRefPubMedCentralPubMed
47.
Yurgelun MB, Goel A, Hornick JL, et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila). 2012;5:574–582.CrossRef
48.
Pino MS, Mino-Kenudson M, Wildemore BM, et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn. 2009;11:238–247.CrossRefPubMedCentralPubMed
49.
Meijer TW, Hoogerbrugge N, Nagengast FM, et al. In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology. 2009;55:414–422.CrossRefPubMed
50.
Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30:1058–1063.CrossRefPubMedCentralPubMed
51.
Wei EK, Colditz GA, Giovannucci EL, et al. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses’ Health Study. Am J Epidemiol. 2009;170:863–872.CrossRefPubMedCentralPubMed
52.
Colorectal Cancer 2011 Report. Volume 2014: World cancer research fund global network, 2011.
53.
Von Karsa L, Anttila A, Ronco G et al. Cancer screening in the European Union, report on the implementation of the council recommendation on cancer screening—first report. In: Cancer. IAfRo, ed. Luxembourg: European Commission, 2008.
54.
USPSTF. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–637.CrossRef
55.
Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. In: Australian National Health & Medical Research Council; Cancer Council Australia ACN, ed, 2005.
56.
Ranger GS. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res. 2014;34:6277–6282.PubMed
57.
58.
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884.CrossRefPubMed
59.
Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895.CrossRefPubMed
60.
Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674–1682.CrossRefPubMed
61.
Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756–1764.CrossRefPubMed
62.
Arber N, Spicak J, Racz I, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 2011;106:1135–1146.CrossRefPubMed
63.
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009;2:310–321.CrossRef
64.
Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin N Am. 2002;82:905–941.CrossRefPubMed
65.
Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256–266.CrossRefPubMed
66.
Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–527.CrossRefPubMed
67.
Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–1750.CrossRefPubMed
68.
69.
Mathers JC, Movahedi M, Macrae F, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol. 2012;13:1242–1249.CrossRefPubMed
70.
Savage RL, Moller PW, Ballantyne CL, et al. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum. 1993;36:84–90.CrossRefPubMed
71.
Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108–1115.CrossRefPubMed
72.
Force USPST. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146:361–364.CrossRef
73.
Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S–e668S.CrossRefPubMedCentralPubMed
74.
Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol Ann Oncol. 2014;2015:47–57.
75.
Ritov I, Baron J. Reluctance to vaccinate: omission bias and ambiguity. J Behav Decis Mak. 1990;3:263–277.CrossRef
76.
Metadata
Title
Practical Opportunities to Improve Early Detection and Prevention of Colorectal Cancer (CRC) in Members of High-Risk Families
Authors
S. G. Patel
J. T. Lowery
D. Gatof
D. J. Ahnen
Publication date
01-03-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3567-2

Other articles of this Issue 3/2015

Digestive Diseases and Sciences 3/2015 Go to the issue

In Memorium

Tribute to Emmet Keeffe

Review

Flexible Sigmoidoscopy: More Than a Unilateral Breast Exam?

Review

Multi-Target Stool DNA Test: A New High Bar for Noninvasive Screening

Review

Colonoscopy: The Current King of the Hill in the USA

Editorial

CRC Screening, Past, Present, and Future: A Tribute to Emmet Keeffe

Review

The History of Colorectal Cancer Screening: A Personal Perspective
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits